Abstract
BackgroundPoly ADP-ribose polymerase inhibitors (PARPi) treatment has radically changed the treatment strategy for epithelial ovarian cancer. Cancer progression with PARPi maintenance is a new problem that has arisen in clinical...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have